Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

nd uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.

DENDREON CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Revenue
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 One of ... rise of personalized medicine, which is the practice of ... treatments to a patient,s individual biology. Personalized diagnostics—laboratory analyses ... major role in the lab,s future. This fall, ... feature the latest science in this exciting field and ...
(Date:8/1/2014)... Once a decision has been made ... will discuss how to define your tolerance for lowest ... Allen, Senior Director of Facilities Integration at Fluor Industrial ... Industrial Services, and special guest Carrier Li, Director in ... as they provide an examination of the Conceptual Design ...
(Date:8/1/2014)... 01, 2014 Testing the mechanical ... a better understanding embryonic development. How and ... structurally and functionally distinct tissues is important because ... Prof. Todd McDevitt, Melissa Kinney, and Rabbia Saeed ... with biochemical cues to control many aspects of ...
(Date:7/31/2014)... CHICAGO , July 31, 2014 Nearly ... 65 th Annual Meeting & Clinical Lab Expo ... The meeting featured never-before-seen breakthroughs in diagnostic research and ... treatment they need. As of Wednesday, July ... 2014 AACC Annual Meeting & Clinical Lab Expo, with ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Study Links Biomechanics and Gene Expression in Stem Cells 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3
... business has some sort of method of disposing of its old ... them to an asset management company, leasing firm, or recycler. It ... does your home look like? Are your closets or basements cluttered ... forever lost its remote? , ,The difference may be due to ...
... July 2006 edition of MedAd News sustains that the ... Aug, 23, 2004, I wrote an article for this publication on ... " , ,In this article I reviewed a number of key ... back to the 1970s and perhaps the year Genentech and Amgen ...
... - Dane County political and economic development leaders have ... of the area Collaboration Council has surpassed the $1 million ... once faced even greater regional challenges than Dane County. , ... president of the Metro Denver Economic Development Corp ., ...
Cached Biology Technology:Computer recycling: An environmental mandate the private sector can support 2Computer recycling: An environmental mandate the private sector can support 3Computer recycling: An environmental mandate the private sector can support 4At 30, biotech is an industry at a crossroads 2At 30, biotech is an industry at a crossroads 3At 30, biotech is an industry at a crossroads 4At 30, biotech is an industry at a crossroads 5At 30, biotech is an industry at a crossroads 6At 30, biotech is an industry at a crossroads 7Can Dane Co. and Wisconsin learn from Denver? 2Can Dane Co. and Wisconsin learn from Denver? 3Can Dane Co. and Wisconsin learn from Denver? 4
(Date:7/31/2014)... Foundation (NSF), counters a widely-held scientific view that ... that certain Arctic lakes store more greenhouse gases ... The study, published this week in the journal ... occur as permafrost thaws and creates surface depressions ... was previously frozen land into lakes. , The ...
(Date:7/31/2014)... long-term follow-up study (HPV-023; NCT00518336) shows the ... human papilloma virus (HPV) vaccine Cervarix. Women ... followed for more than nine years, and ... 100%. This is the longest follow-up report ... https://www.landesbioscience.com/journals/vaccines/article/29532/ for the full paper. , ...
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... cap is good for you, at least if you are ... in Oncology Center have shown that in healthy cells, a ... genetic storehouse, in its proper place. Understanding this cap,s influence ... clues to the diagnosis and treatment of diseases such as ...
... , REDWOOD CITY, Calif., Dec. 2 DigitalPersona, Inc., ... announced an agreement with IBM to deploy a new ... SurePOS 500 retail systems. The DigitalPersona U.are.U® 4500HD offering ... users so that specific transactions can be linked to ...
... prescribed beta 2 adrenergic agonist drugs for the treatment of ... increase the incidence of autism-spectrum disorders, psychiatric pathology, cognitive problems ... new study published in the December 2009 issue of the ... 2 adrenergic agonist drugs as a class are widely used ...
Cached Biology News:A cell's 'cap' of bundled fibers could yield clues to disease 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2